Inhibikase Therapeutics, Inc. annual report, FY2023

Inhibikase Therapeutics, Inc. 2023 Form 10-K Summary

Reporting period: Fiscal year ended December 31, 2023. This is an annual Form 10-K; the filing does not provide a separate fourth-quarter income statement.

Business Context

Inhibikase is a clinical-stage pharmaceutical company with no approved commercial products or product sales. Its lead candidate, risvodetinib (IkT-148009), is a selective Abelson tyrosine kinase inhibitor being developed for Parkinson’s disease and related disorders, including Multiple System Atrophy (MSA). The company is also developing IkT-001Pro, a prodrug of imatinib intended initially for stable-phase chronic myelogenous leukemia.

The Phase 2 Parkinson’s 201 trial was initiated in January 2023 following the FDA’s lifting of a clinical hold.
As of March 22, 2024, 32 trial sites were active, 73 participants had been enrolled, and 34 had completed the 12-week dosing period.
The company plans a 12-month extension of the 201 trial, subject to securing additional resources.
Risvodetinib received FDA Orphan Drug Designation for MSA in October 2023; the company plans a Phase 2 MSA study involving at least 120 patients, subject to funding.
IkT-001Pro completed a 66-volunteer dose-finding and dose-equivalence study. Management intends to pursue a 505(b)(2) NDA pathway.

Key Financial Metrics

Metric	2023	2022	Change
Grant revenue	$260,501	$123,440	+111.0%
Research and development expense	$13.62 million	$12.03 million	+13.2%
Selling, general and administrative expense	$6.73 million	$6.22 million	+8.3%
Loss from operations	$(20.09) million	$(18.13) million	Worsened by $1.96 million
Interest income	$1.06 million	$74,453	+1,324.9%
Net loss	$(19.03) million	$(18.05) million	Worsened by $0.97 million
Basic and diluted loss per share	$(3.57)	$(4.28)	Improved on higher share count
Net cash used in operating activities	$(18.09) million	$(17.35) million	Use increased by $0.73 million

Revenue consisted entirely of federal research grant revenue, with 100% derived from a single U.S. government source. The company has not generated revenue from product sales.

Margins, Liquidity and Capitalization

Operating margin was approximately negative 7,721%, based on grant revenue and operating loss; the metric is not economically meaningful because the company is pre-commercial and grant-funded.
Cash and cash equivalents were $9.17 million at December 31, 2023, compared with $7.19 million at December 31, 2022.
Marketable securities were $4.09 million, down from $15.86 million.
Working capital was $10.77 million, compared with $20.68 million at December 31, 2022.
Accumulated deficit was $66.90 million.
Total liabilities were $3.53 million, including $381,784 of insurance-premium financing payable and $240,219 of operating lease liabilities.
The insurance-premium financing bears interest at 8.59% and is payable through December 2024. The filing does not identify material conventional term debt or a revolving credit facility.
Net cash increased by $1.98 million during 2023, primarily because $8.54 million of financing proceeds and $11.66 million of net investment maturities exceeded operating cash use.
The January 2023 financing generated approximately $8.5 million of net proceeds and increased common shares outstanding to 6.19 million at year-end.

Material Changes Versus 2022

Research and development spending increased $1.58 million, driven primarily by a $1.51 million increase in CML-related expenditures; Parkinson’s spending declined $0.61 million.
SG&A increased $0.51 million, primarily due to higher investor-relations and employee costs, partly offset by lower directors-and-officers insurance and legal and consulting costs.
Interest income increased substantially as the company invested cash in U.S. Treasury securities and money-market instruments.
Marketable securities declined by $11.77 million as securities matured and funded operations and other uses.
Common shares outstanding increased by approximately 1.96 million shares during 2023, primarily from the January financing and exercise of pre-funded warrants.
Warrants outstanding increased materially. At December 31, 2023, 2.27 million warrant shares and 839,523 option shares were excluded from diluted loss per share because they were anti-dilutive.
The company completed a 1-for-6 reverse stock split on June 30, 2023; historical share and per-share data were retroactively adjusted.

Guidance, Outlook and Management Commentary

Management estimates that year-end working capital plus proceeds from the February 2024 ATM program should fund normal operations into the first quarter of 2025. This estimate depends on assumptions that may prove inaccurate.
The company expects continuing operating losses and negative operating cash flow for the foreseeable future and expects research and development expenses to rise as clinical programs advance.
Management expects the 12-week Parkinson’s 201 trial to be fully enrolled by the end of the third quarter of 2024 or earlier, with results potentially reported in the second half of 2024.
The planned 12-month extension study will begin only after adequate resources are secured.
Following the January 2024 pre-NDA meeting, the FDA indicated that 505(b)(2) appears to be an appropriate pathway for IkT-001Pro, subject to formal review of the clinical data and completion of additional dose, absorption, manufacturing and quality-control work.
The FDA indicated that additional evaluation may be needed to support doses equivalent to up to 800 mg of imatinib and to assess gut transporter differences and potential medication-mix-up risks.
In February 2024, the company established an ATM facility permitting sales of up to approximately $5.7 million. As of the filing date, 290,564 shares had been sold and net proceeds were $777,910.

Principal Risks, Contingencies and Unusual Items

The auditors included a going-concern explanatory paragraph. The company states that substantial doubt exists regarding its ability to continue as a going concern for one year after issuance of the financial statements.
Additional equity, debt, grant or partnership financing is required. Future equity financing could dilute existing stockholders; debt financing could impose restrictive covenants.
The company has no approved products, no product revenue and no commercial sales or marketing infrastructure.
Risvodetinib programs previously experienced an FDA clinical hold in November 2022. The hold was lifted for Parkinson’s disease in January 2023 and MSA in March 2023, but future holds or additional regulatory requirements remain possible.
Evidence of potential Parkinson’s benefit was based on only 11 withdrawn participants, including three participants at the 200 mg dose; management expressly states that the sample is too small to establish clinical benefit.
IkT-001Pro remains subject to additional regulatory, clinical, preclinical, manufacturing and quality-control requirements, and the 505(b)(2) pathway is not assured.
The company relies heavily on contract research organizations, academic collaborators and third-party manufacturers, including manufacturers in China, with no redundant supply arrangements.
All novel and in-licensed compounds were funded in whole or in part by the U.S. government and may be subject to federal march-in rights and related requirements.
Intellectual-property protection remains subject to patent validity, enforceability, ownership, licensing and infringement risks.
The company reported no material litigation and stated that cybersecurity threats had not materially affected operations as of the filing.

Investor Verification Checklist

Verify the company’s actual cash burn after the filing date and whether the ATM program has generated additional proceeds.
Confirm the enrollment pace, completion status, safety data and statistical plan for the Parkinson’s 201 trial.
Determine whether the 12-month 201 trial extension has begun and whether funding is sufficient to complete it.
Assess whether FDA feedback on IkT-001Pro requires additional clinical or preclinical studies before an NDA can be filed.
Reconcile outstanding warrants, options, pre-funded warrants and potential dilution against the reported share count.
Review the going-concern disclosure and management’s contingency plans if additional capital is unavailable.
Evaluate whether the company’s cash runway estimate includes the planned MSA study, the 201 trial extension and other discretionary programs.
Monitor future FDA actions, clinical holds, adverse events, trial results and manufacturing-readiness updates.